198 related articles for article (PubMed ID: 33067731)
1. Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.
Kondo N; Oishi A; Hirata M; Temma T
Ann Nucl Med; 2021 Jan; 35(1):83-91. PubMed ID: 33067731
[TBL] [Abstract][Full Text] [Related]
2. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
3. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
4. Development of an
Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
[TBL] [Abstract][Full Text] [Related]
5. Development of novel radioiodinated exendin-4 derivatives targeting GLP-1 receptor for detection of β-cell mass.
Ogawa Y; Kimura H; Fujimoto H; Kawashima H; Toyoda K; Mukai E; Yagi Y; Ono M; Inagaki N; Saji H
Bioorg Med Chem; 2021 Dec; 52():116496. PubMed ID: 34808404
[TBL] [Abstract][Full Text] [Related]
6. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.
Kiesewetter DO; Gao H; Ma Y; Niu G; Quan Q; Guo N; Chen X
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):463-73. PubMed ID: 22170321
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
8. Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.
Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Yabe D; Inagaki N
J Diabetes Investig; 2020 Nov; 11(6):1448-1456. PubMed ID: 32323451
[TBL] [Abstract][Full Text] [Related]
9. Structure-Activity Relationships and Pharmacokinetics of
Iikuni S; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Aug; 19(8):2832-2839. PubMed ID: 35757958
[TBL] [Abstract][Full Text] [Related]
10. Targeted Optical Imaging of the Glucagonlike Peptide 1 Receptor Using Exendin-4-IRDye 800CW.
Boss M; Bos D; Frielink C; Sandker G; Ekim S; Marciniak C; Pattou F; van Dam G; van Lith S; Brom M; Gotthardt M; Buitinga M
J Nucl Med; 2020 Jul; 61(7):1066-1071. PubMed ID: 31924726
[TBL] [Abstract][Full Text] [Related]
11. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
[TBL] [Abstract][Full Text] [Related]
12. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of A Novel GLP-1R Ligand for PET Imaging of Prostate Cancer.
Yue Y; Xu Y; Huang L; Pan D; Bai Z; Wang L; Yang R; Yan J; Song H; Li X; Yang M
Anticancer Agents Med Chem; 2019; 19(4):509-514. PubMed ID: 30068284
[TBL] [Abstract][Full Text] [Related]
15. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
[TBL] [Abstract][Full Text] [Related]
16. Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor-Positive Lesions.
Boss M; Bos D; Frielink C; Sandker G; Bronkhorst P; van Lith SAM; Brom M; Buitinga M; Gotthardt M
J Nucl Med; 2020 Nov; 61(11):1588-1593. PubMed ID: 32385165
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Boss M; Gotthardt M; Scarlattei M; Baldari G; Silva C; Bonadonna RC; Ruffini L
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056858
[No Abstract] [Full Text] [Related]
18. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
20. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
